Cargando…
Development of Antibody-Based Therapeutics Translational Considerations /
Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics req...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2012.
|
| Edición: | 1st ed. 2012. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-4419-5955-3 | ||
| 003 | DE-He213 | ||
| 005 | 20220119210520.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 120423s2012 xxu| s |||| 0|eng d | ||
| 020 | |a 9781441959553 |9 978-1-4419-5955-3 | ||
| 024 | 7 | |a 10.1007/978-1-4419-5955-3 |2 doi | |
| 050 | 4 | |a RS1-441 | |
| 072 | 7 | |a MQP |2 bicssc | |
| 072 | 7 | |a MED072000 |2 bisacsh | |
| 072 | 7 | |a MQP |2 thema | |
| 082 | 0 | 4 | |a 615.1 |2 23 |
| 245 | 1 | 0 | |a Development of Antibody-Based Therapeutics |h [electronic resource] : |b Translational Considerations / |c edited by Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp. |
| 250 | |a 1st ed. 2012. | ||
| 264 | 1 | |a New York, NY : |b Springer New York : |b Imprint: Springer, |c 2012. | |
| 300 | |a XIV, 426 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Translational Strategies for Development of Antibody-Based Therapeutics: An Overview -- Discovery Process for Antibody-Based Therapeutics -- Technologies for the Generation of Human Antibodies -- Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics -- Biophysical Considerations -- Considerations in Establishing Affinity Design Goals -- BioAnalytical Considerations: Pharmacokinetics and Immunogenicity -- Antibody-Based Therapeutics in Oncology : Preclinical Considerations -- Factors Impacting the Tumor Localization and Distribution -- Antibody-Based Therapeutics: Preclinical Safety Considerations -- Application of Pharmacokinetic/Pharmacodynamic Modeling -- Design of Translational Strategies : Application of Population Pharmacokinetic-Pharmacodynamic (PK-PD) Approaches -- Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics -- Development of Antibody-Based Therapeutics: Translational Research in Alzheimer's Disease -- Considerations in Manufacturing Process Development -- Next Generation Antibody-Based Therapeutics -- Immune Complex Therapies for Treatment of Immune Thrombocytopenia (ITP) -- Application of Bioinformatics Principles for Target Evaluation -- Concluding Remarks. | |
| 520 | |a Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in "relevant" animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics. | ||
| 650 | 0 | |a Pharmacy. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Biochemistry. | |
| 650 | 1 | 4 | |a Pharmacy. |
| 650 | 2 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Biochemistry. |
| 700 | 1 | |a Tabrizi, Mohammad A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Bornstein, Gadi G. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Klakamp, Scott L. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781441959645 |
| 776 | 0 | 8 | |i Printed edition: |z 9781441959539 |
| 776 | 0 | 8 | |i Printed edition: |z 9781489991133 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-4419-5955-3 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||